Latest Articles

Publication Date
All News Scientific
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity - TipRanks

Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity TipRanks

Published: Jan. 14, 2026, 4:33 p.m.
Read Full Article
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer - Targeted Oncology

Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer Targeted Oncology

Published: Jan. 11, 2026, 4:14 p.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com UK

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com UK

Published: Jan. 9, 2026, 2:25 p.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com

Published: Jan. 9, 2026, 1:59 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.
Read Full Article
Using Lenvatinib/Pembrolizumab for Endometrial Cancer in Clinical Practice - Targeted Oncology

Using Lenvatinib/Pembrolizumab for Endometrial Cancer in Clinical Practice Targeted Oncology

Published: Jan. 5, 2026, 1:27 p.m.
Read Full Article
Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology

Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology

Published: Jan. 5, 2026, 1:12 p.m.
Read Full Article
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy - Targeted Oncology

Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy Targeted Oncology

Published: Jan. 5, 2026, 1:07 p.m.
Read Full Article
Multi-omics analysis reveals shared diagnostic and therapeutic targets in endometriosis and recurrent implantation failure - Nature

Multi-omics analysis reveals shared diagnostic and therapeutic targets in endometriosis and recurrent implantation failure Nature

Published: Dec. 29, 2025, 6:01 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!